Repurposing Metformin for Dermatological Use: Mechanisms, Evidence, and Clinical Perspectives
Dermato · 02.03.2026 · 6 (1) · 8
DOI: 10.3390/dermato6010008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermato, online erschienen am 02.03.2026. Verfasst von Patrícia Mathias Döll-Boscardin und 8 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Metformin, a widely used antidiabetic drug, has recently gained attention in dermatology due to its pleiotropic effects. Given the high prevalence, chronicity, and therapeutic challenges of several dermatological conditions, there is growing interest in repurposing metformin as a topical agent with anti-inflammatory, antioxidant, metabolic, and regenerative properties. This narrative review aimed to synthesize and critically analyze the available preclinical and clinical evidence regarding the mechanisms of action, efficacy, safety, and therapeutic potential of topical metformin across different skin disorders.
Methods
A literature search was conducted in PubMed and complementary databases for studies published between 2015 and 2025 addressing topical metformin in dermatology, including experimental, observational, interventional, and review articles.
Results
The findings indicate that topical metformin has been associated with beneficial biological effects in conditions such as melasma, photoaging, wound healing, psoriasis, acne, skin cancer, and hair disorders, largely through AMPK activation, modulation of inflammation and oxidative stress, inhibition of melanogenesis, enhancement of tissue regeneration, and regulation of immune and metabolic pathways, although evidence remains predominantly preclinical and methodologically heterogeneous.
Conclusions
Topical metformin represents a promising investigational multifunctional dermatological agent; however, its clinical translation depends on well-designed randomized controlled trials with standardized formulations, adequate sample sizes, and long-term follow-up to establish its efficacy, safety, and optimal therapeutic protocols.
Zitieren
APA
Döll-Boscardin, P. M., Woinarovicz, A. C., Sousa, C. B. D., Antunes, E. L., Lessa, F. M. D. S., Mackeivicz, G. A. O., Macedo, J. B. D., Kapp, M., & Machinski, I. (2026). Repurposing Metformin for Dermatological Use: Mechanisms, Evidence, and Clinical Perspectives. Dermato, 6(1), 8. https://doi.org/10.3390/dermato6010008
Vancouver
Döll-Boscardin PM, Woinarovicz AC, Sousa CBD, Antunes EL, Lessa FMDS, Mackeivicz GAO, et al. Repurposing Metformin for Dermatological Use: Mechanisms, Evidence, and Clinical Perspectives. Dermato. 2026;6(1):8. doi:10.3390/dermato6010008
BibTeX
@article{DllBoscardin2026,
author = {Döll-Boscardin, Patrícia Mathias and Woinarovicz, Amábile Cristine and Sousa, Carolina Bacila de and Antunes, Edher Lucas and Lessa, Frederico Machado de Sousa and Mackeivicz, Giselle Ariana Otto and Macedo, Júlia Borges de and Kapp, Mariana and Machinski, Isadora},
title = {Repurposing Metformin for Dermatological Use: Mechanisms, Evidence, and Clinical Perspectives},
journal = {Dermato},
year = {2026},
volume = {6},
number = {1},
pages = {8},
doi = {10.3390/dermato6010008}
}
EUVIMED